Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics

被引:67
作者
Bhale, Aishwarya Sudam [1 ]
Venkataraman, Krishnan [1 ]
机构
[1] Vellore Inst Technol, Ctr Bioseparat Technol, Vellore 632014, Tamil Nadu, India
关键词
Apolipoprotein A1 (ApoA1); High -density lipoproteins (HDL); Mutations; Cardiovascular diseases; Amyloidosis; Mimetic peptides; APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEINS; REVERSE CHOLESTEROL TRANSPORT; AMINO-ACID-SEQUENCE; IMILANO APOPROTEIN; CRYSTAL-STRUCTURE; ATHEROSCLEROSIS; VARIANT; METABOLISM; INSIGHTS;
D O I
10.1016/j.biopha.2022.113634
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Apolipoprotein A1 (ApoA1) is a member of the Apolipoprotein family of proteins. It's a vital protein that helps in the production of high-density lipoprotein (HDL) particles, which are crucial for reverse cholesterol transport (RCT). It also has anti-inflammatory, anti-atherogenic, anti-apoptotic, and anti-thrombotic properties. These functions interact to give HDL particles their cardioprotective characteristics. ApoA1 has recently been inves-tigated for its potential role in atherosclerosis, diabetes, neurological diseases, cancer, and certain infectious diseases. Since ApoA1's discovery, numerous mutations have been reported that affect its structural integrity and alter its function. Hence these insights have led to the development of clinically relevant peptides and synthetic reconstituted HDL (rHDL) that mimics the function of ApoA1. As a result, this review has aimed to provide an organized explanation of our understanding of the ApoA1 protein structure and its role in various essential pathways. Furthermore, we have comprehensively reviewed the important ApoA1 mutations (24 mutations) that are reported to be involved in various diseases. Finally, we've focused on the therapeutic potentials of some of the beneficial mutations, small peptides, and synthetic rHDL that are currently being researched or developed, since these will aid in the development of novel therapeutics in the future.
引用
收藏
页数:18
相关论文
共 180 条
[1]   Dual Role of an N-terminal Amyloidogenic Mutation in Apolipoprotein A-I DESTABILIZATION OF HELIX BUNDLE AND ENHANCEMENT OF FIBRIL FORMATION [J].
Adachi, Emi ;
Nakajima, Hiroyuki ;
Mizuguchi, Chiharu ;
Dhanasekaran, Padmaja ;
Kawashima, Hiroyuki ;
Nagao, Kohjiro ;
Akaji, Kenichi ;
Lund-Katz, Sissel ;
Phillips, Michael C. ;
Saito, Hiroyuki .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (04) :2848-2856
[2]   Risk of Atherosclerosis in Patients with Ataxia Telangiectasia [J].
Alves Andrade, Itana Gomes ;
Costa-Carvalho, Beatriz Tavares ;
da Silva, Rosangela ;
Hix, Sonia ;
Kochi, Cristiane ;
Suano-Souza, Fabola Isabel ;
Saccardo Sarni, Roseli Oselka .
ANNALS OF NUTRITION AND METABOLISM, 2015, 66 (04) :196-201
[3]   Selective HDL-Raising Human Apo A-I Gene Therapy Counteracts Cardiac Hypertrophy, Reduces Myocardial Fibrosis, and Improves Cardiac Function in Mice with Chronic Pressure Overload [J].
Amin, Ruhul ;
Muthuramu, Ilayaraja ;
Aboumsallem, Joseph Pierre ;
Mishra, Mudit ;
Jacobs, Frank ;
De Geest, Bart .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (09)
[4]   Implication of the rs670 variant of APOA1 gene with lipid profile, serum adipokine levels and components of metabolic syndrome in adult obese subjects [J].
Antonio de Luis, Daniel ;
Izaola, Olatz ;
Primo, David ;
Aller, Rocio .
CLINICAL NUTRITION, 2019, 38 (01) :407-411
[5]   Apolipoprotein A-I: the dual face of a protein [J].
Arciello, Angela ;
Piccoli, Renata ;
Monti, Daria Maria .
FEBS LETTERS, 2016, 590 (23) :4171-4179
[6]   Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1 [J].
Asl, LH ;
Liepnieks, JJ ;
Asl, KH ;
Uemichi, T ;
Moulin, G ;
Desjoyaux, E ;
Loire, R ;
Delpech, M ;
Grateau, G ;
Benson, MD .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) :221-227
[7]   The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity [J].
Azmi, Shazli ;
Ferdousi, Maryam ;
Liu, Yifen ;
Adam, Safwaan ;
Siahmansur, Tarza ;
Ponirakis, Georgios ;
Marshall, Andrew ;
Petropoulos, Ioannis N. ;
Ho, Jan Hoong ;
Syed, Akheel A. ;
Gibson, John M. ;
Ammori, Basil J. ;
Durrington, Paul N. ;
Malik, Rayaz A. ;
Soran, Handrean .
SCIENTIFIC REPORTS, 2021, 11 (01)
[8]   Identification and differential expression of serotransferrin and apolipoprotein A-I in the plasma of HIV-1 patients treated with first-line antiretroviral therapy [J].
Barik, Sushanta Kumar ;
Mohanty, Keshar Kunja ;
Mohanty, Ashok Kumar ;
Rawat, Preeti ;
Gopal, G. ;
Bisht, Deepa ;
Patil, Shripad A. ;
Singh, Rananjay ;
Sharma, Devesh ;
Tripathy, Srikanth Prasad ;
Tandon, Rekha ;
Singh, Tej Pal ;
Jena, Srikanta .
BMC INFECTIOUS DISEASES, 2020, 20 (01)
[9]   Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I [J].
Bielicki, JK ;
Oda, MN .
BIOCHEMISTRY, 2002, 41 (06) :2089-2096
[10]   Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response [J].
Bindu, Hima G. ;
Rao, Veena S. ;
Kakkar, Vijay V. .
CHOLESTEROL, 2011,